Literature DB >> 22126292

miRNA therapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs.

Enrica Fabbri1, Eleonora Brognara, Monica Borgatti, Ilaria Lampronti, Alessia Finotti, Nicoletta Bianchi, Stefano Sforza, Tullia Tedeschi, Alex Manicardi, Rosangela Marchelli, Roberto Corradini, Roberto Gambari.   

Abstract

Peptide nucleic acids (PNAs) are DNA/RNA mimics extensively used for pharmacological regulation of gene expression in a variety of cellular and molecular systems, and they have been described as excellent candidates for antisense and antigene therapies. At present, very few data are available on the use of PNAs as molecules targeting miRNAs. miRNAs are a family of small nc RNAs that regulate gene expression by sequence-selective targeting of mRNAs, leading to a translational repression or mRNA degradation to the control of highly regulated biological functions, such as differentiation, cell cycle and apoptosis. The aim of this article is to present the state-of-the-art concerning the possible use of PNAs to target miRNAs and modify their biological metabolism within the cells. The results present in the literature allow to propose PNA-based molecules as very promising reagents to modulate the biological activity of miRNAs. In consideration of the involvement of miRNAs in human pathologies, PNA-mediated targeting of miRNAs has been proposed as a potential novel therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22126292     DOI: 10.2217/epi.11.90

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  19 in total

Review 1.  HypoxamiRs and cancer: from biology to targeted therapy.

Authors:  Harriet E Gee; Cristina Ivan; George A Calin; Mircea Ivan
Journal:  Antioxid Redox Signal       Date:  2013-11-22       Impact factor: 8.401

Review 2.  miR-210: fine-tuning the hypoxic response.

Authors:  Mircea Ivan; Xin Huang
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

3.  Psoralen derivatives as inhibitors of NF-κB interaction: the critical role of the furan ring.

Authors:  Giovanni Marzaro; Ilaria Lampronti; Monica Borgatti; Paolo Manzini; Roberto Gambari; Adriana Chilin
Journal:  Mol Divers       Date:  2015-04-14       Impact factor: 2.943

4.  Targeting pre-miRNA by peptide nucleic acids: a new strategy to interfere in the miRNA maturation.

Authors:  Concetta Avitabile; Michele Saviano; Luca D'Andrea; Nicoletta Bianchi; Enrica Fabbri; Eleonora Brognara; Roberto Gambari; Alessandra Romanelli
Journal:  Artif DNA PNA XNA       Date:  2012-04-01

5.  MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.

Authors:  Christopher J Cheng; Raman Bahal; Imran A Babar; Zachary Pincus; Francisco Barrera; Connie Liu; Alexander Svoronos; Demetrios T Braddock; Peter M Glazer; Donald M Engelman; W Mark Saltzman; Frank J Slack
Journal:  Nature       Date:  2014-11-17       Impact factor: 49.962

Review 6.  MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics.

Authors:  Jyotika Varshney; Subbaya Subramanian
Journal:  Front Mol Biosci       Date:  2015-06-17

7.  Do epigenetic marks govern bone mass and homeostasis?

Authors:  Jesús Delgado-Calle; Pablo Garmilla; José A Riancho
Journal:  Curr Genomics       Date:  2012-05       Impact factor: 2.236

Review 8.  The Role of Epigenetics in Arterial Calcification.

Authors:  Shan-Shan Wu; Xiao Lin; Ling-Qing Yuan; Er-Yuan Liao
Journal:  Biomed Res Int       Date:  2015-06-29       Impact factor: 3.411

9.  MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression.

Authors:  Pedro M Costa; Maria C Pedroso de Lima
Journal:  Pharmaceuticals (Basel)       Date:  2013-09-30

Review 10.  From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review).

Authors:  Roberta Piva; Demetrios A Spandidos; Roberto Gambari
Journal:  Int J Oncol       Date:  2013-08-12       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.